About: Joachim Yahalom

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Joachim Yahalom Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

American-Israeli radiation oncologist

Attributes	Values
rdf:type	Item
description	հետազոտող (hy) onderzoeker (nl) American-Israeli radiation oncologist (en)
rdfs:label	Joachim Yahalom (cs) Joachim Yahalom (en) Joachim Yahalom (es) Joachim Yahalom (nl) Joachim Yahalom (sl) Joachim Yahalom (ast) יואכים יהלום (he)
skos:prefLabel	Joachim Yahalom (cs) Joachim Yahalom (en) Joachim Yahalom (es) Joachim Yahalom (nl) Joachim Yahalom (sl) Joachim Yahalom (ast) יואכים יהלום (he)
name	Joachim Yahalom (cs) Joachim Yahalom (en) Joachim Yahalom (es) Joachim Yahalom (nl) Joachim Yahalom (sl) Joachim Yahalom (ast) יואכים יהלום (he)
affiliation	wds:Q50056528-b6c7e466-40bc-b8c8-2c49-99ff3ea1e59d
affiliation	Memorial Sloan Kettering Cancer Center
given name	wds:Q50056528-61D56FA2-A5BF-4F41-9829-5064483552F4
given name	Joachim
instance of	wds:Q50056528-B689862B-3A4A-4858-B02B-AB8E690ECDC6
NL CR AUT ID	wds:Q50056528-ec92f4c8-4077-5cad-f237-19b4278d0edc
instance of	Homo sapiens
NL CR AUT ID	xx0124230
Nationale Thesaurus voor Auteursnamen ID	wds:Q50056528-e5778b35-43f6-0217-e172-a972a6e9d46d
occupation	wds:Q50056528-2e61ca11-4a5a-c9f8-0988-066abc7f8b11
employer	wds:Q50056528-0c79fcf0-4b47-3496-a4a9-e23c28579a6d
sex or gender	wds:Q50056528-5d0c1b55-4bd8-4b1d-adfb-cc1d405c1f28
VIAF ID	wds:Q50056528-fc3485b6-4363-9171-4a62-9139a0d1919e
Library of Congress authority ID	wds:Q50056528-7b628754-4ef2-b011-9ddb-679518a4bca6
country of citizenship	wds:Q50056528-ac4c1cc9-44fc-ca40-714b-318d43a7fd93 wds:Q50056528-f2244bbf-45ed-9961-1ac6-caa728ea546a
educated at	wds:Q50056528-abeb587b-4a74-60c2-8214-a1578c62cba7
family name	wds:Q50056528-a44a9747-434b-3d1d-fbd4-eaaab69f8fd6
Canadiana Name Authority ID	wds:Q50056528-34c8c2f3-42f4-ff38-a9c1-56ddae1c6b32
National Library of Israel J9U ID	wds:Q50056528-90e9d8b9-478c-6d29-c25a-53782199ffae
Nationale Thesaurus voor Auteursnamen ID	http://data.bibliotheken.nl/id/thes/p310283345
VIAF ID	http://viaf.org/viaf/11838721
Library of Congress authority ID	http://id.loc.gov/authorities/names/nb2008010306
Nationale Thesaurus voor Auteursnamen ID	310283345
occupation	radiation oncologist
employer	Memorial Sloan Kettering Cancer Center
sex or gender	male
VIAF ID	11838721
Library of Congress authority ID	nb2008010306
country of citizenship	Israel United States of America
educated at	Hebrew University of Jerusalem
family name	Yahalom
Canadiana Name Authority ID	ncf11557116
National Library of Israel J9U ID	987007379126905171
ORCID iD	wds:Q50056528-9915F5DB-453C-449B-820E-D3F587D5A0F2
ORCID iD	https://orcid.org/0000-0003-1658-8585
ORCID iD	0000-0003-1658-8585
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q50056528
is author of	High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone The relationship between twenty missense ATM variants and breast cancer risk: the Multiethnic Cohort. Effect of epidermal growth factor on the growth and radiation sensitivity of human breast cancer cells in vitro Long-term survival in primary CNS lymphoma Multiple myeloma, version 1.2013. Primary breast irradiation in large-breasted or heavy women: analysis of cosmetic outcome T cell-depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma Delayed neurotoxicity in primary central nervous system lymphoma Report from the Rockefellar Foundation Sponsored International Workshop on reducing mortality and improving quality of life in long-term survivors of Hodgkin's disease: July 9-16, 2003, Bellagio, Italy Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma Combined modality therapy for primary CNS lymphoma Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group. Autologous bone marrow transplantation Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome Whole-brain radiotherapy in primary CNS lymphoma Re-Examining the Role of Radiation Therapy for Diffuse Large B-Cell Lymphoma in the Modern Era Non-Hodgkin's lymphomas, version 4.2014. Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. Second malignant neoplasms and cardiovascular disease following radiotherapy Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy. The influence of older age on breast cancer treatment decisions and outcome Non-Hodgkin's lymphomas, version 2.2014 NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Second malignant neoplasms and cardiovascular disease following radiotherapy Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017. NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software